Clinical insights on treatment after CAR-T therapy and expanding outpatient use
— Clinical insights on treatment after CAR-T therapy and expanding outpatient use
by Gregory Laub, Senior Director, Video, MedPage Today
July 9, 2026
• 3 min read
Real-world data presented at the American Society of Clinical Oncology (ASCO) annual meeting reinforced the effectiveness and safety of bispecific antibodies for relapsed or refractory follicular lymphoma, including in patients with high-risk disease features.
High response rates and manageable safety were seen across high-risk patient groups
'Some of the most effective therapies we have,' says Loretta Nastoupil
VIDEO: CAR-T in the frontline setting, other promising areas of research in myeloma
In this video, Adriana Rossi, MD, assistant professor of medicine at Mount Sinai, highlights upcoming clinical trials in multiple…
Johnson & Johnson has unveiled massive phase 3 survival data for its dual bispecific combination in earlier-line multiple…
Lilly’s $7bn acquisition of Kelonia seems to be bearing fruit, with other in vivo approaches showing promise at ASCO 2026.
